Multiple Sclerosis Trial, Recruiting NCT04573673 Sponsor: University Hospital, Lille Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT04573673
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with multiple sclerosis
  • People who have a condition called bladder-sphincter dyssynergia, where the bladder and its outlet do not work together properly
  • People who manage their bladder entirely by using a self-catheter inserted by themselves (called clean intermittent self-catheterisation), with no other bladder management method
  • People who are willing to sign a written consent form to take part
  • People who have health insurance coverage (confirm with trial site regarding which types of coverage are accepted)
  • People who are willing to follow all study procedures for the full duration of the trial

Who may not be able to join:

  • People who have another neurological condition in addition to multiple sclerosis
  • People who score 6 or higher on a standard disability scale used for multiple sclerosis (called the EDSS scale), which generally reflects a significant level of walking difficulty
  • People who have had more than 3 urinary tract infections in the past year
  • People who have overactive bladder that is not well controlled
  • People who have uncontrolled involuntary bladder muscle contractions (detrusor hyperactivity)
  • People who have a problem with how the bladder stretches to store urine (bladder compliance disorder)
  • People who have had tibial nerve stimulation treatment in the past 3 months
  • People who are currently being treated with sacral nerve stimulation
  • People who have received botulinum toxin A injections into the bladder lining within the past 9 months
  • People who have taken alpha-blocker medication within the past month
  • People who have an enlarged prostate with a volume greater than 40cc, confirmed by an ultrasound scan done within the last 6 months
  • People who have one or more pouches (diverticula) on the bladder wall
  • People who have a kidney-related condition affecting one or both kidneys (confirm with trial site for full details, as the source text appears incomplete)
  • People who have urine flowing backward from the bladder toward one or both kidneys (vesico-ureteral reflux)
  • People whose kidneys are not functioning well enough (based on a specific kidney function measurement falling below a set level)
  • People who have a metal prosthesis in a lower limb (leg or foot)
  • People who have a pacemaker fitted
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xavier Biardeau, MD, University Hospital, Lille

Phone: 03.20.44.41.73

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 December 2021
Est. completion
1 June 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

BVE ratio (Bladder Voiding Efficiency) = Ratio of urine volume / total bladder volume

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov